102 related articles for article (PubMed ID: 6387890)
1. Detection of tumour-associated transplantation antigens by syngeneic cytotoxic T lymphocytes after fusion of tumour cell membrane vesicles to recipient cells.
Altevogt P
Scand J Immunol; 1984 Sep; 20(3):255-60. PubMed ID: 6387890
[TBL] [Abstract][Full Text] [Related]
2. Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells.
Altevogt P; Leidig S; Heckl-Oestreicher B
Cancer Res; 1984 Nov; 44(11):5305-13. PubMed ID: 6333273
[TBL] [Abstract][Full Text] [Related]
3. Antigenic variation in cancer metastasis: immune escape versus immune control.
Schirrmacher V; Fogel M; Russmann E; Bosslet K; Altevogt P; Beck L
Cancer Metastasis Rev; 1982; 1(3):241-74. PubMed ID: 6985248
[TBL] [Abstract][Full Text] [Related]
4. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
von Hoegen P; Altevogt P; Schirrmacher V
Cell Immunol; 1987 Oct; 109(2):338-48. PubMed ID: 3117377
[TBL] [Abstract][Full Text] [Related]
5. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
6. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
7. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.
Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D
Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969
[TBL] [Abstract][Full Text] [Related]
8. Immunoresistant metastatic tumor variants can re-express their tumor antigen after treatment with DNA methylation-inhibiting agents.
Altevogt P; von Hoegen P; Schirrmacher V
Int J Cancer; 1986 Nov; 38(5):707-11. PubMed ID: 3490445
[TBL] [Abstract][Full Text] [Related]
9. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
[TBL] [Abstract][Full Text] [Related]
10. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
Weinhold KJ; Wheelock EF
Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
[TBL] [Abstract][Full Text] [Related]
11. Cell surface antigen expression on chemically induced murine leukaemias.
Birch JM; Moore M; Craig AW
Br J Cancer; 1975 Jun; 31(6):630-40. PubMed ID: 1174442
[TBL] [Abstract][Full Text] [Related]
12. Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice.
Schirrmacher V; von Hoegen P; Griesbach A; Schild HJ; Zangemeister-Wittke U
Cancer Immunol Immunother; 1991; 32(6):373-81. PubMed ID: 1826094
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage.
Larizza L; Schirrmacher V; Pflüger E
J Exp Med; 1984 Nov; 160(5):1579-84. PubMed ID: 6491605
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor.
Germain RN; Dorf ME; Benacerraf B
J Exp Med; 1975 Oct; 142(4):1023-8. PubMed ID: 809532
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.
Toffaletti DL; Darrow TL; Scott DW
J Immunol; 1983 Jun; 130(6):2982-6. PubMed ID: 6189910
[TBL] [Abstract][Full Text] [Related]
16. Virus specific antigens in BK virus-transformed cells detected by cell-mediated immune reactions.
Karjalainen HE; Laaksonen AM; Mäntyjärvi RA
Med Biol; 1983 Feb; 61(1):73-8. PubMed ID: 6302408
[TBL] [Abstract][Full Text] [Related]
17. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
18. Expression of polyoma-induced antigens in low malignant hybrids derived from fusion of a polyoma-induced tumour with a fibroblast line.
Meyer G; Berebbi M; Klein G
Nature; 1974 May; 249(452):47-9. PubMed ID: 4364354
[No Abstract] [Full Text] [Related]
19. Capacity of different cell types to stimulate cytotoxic T lymphocyte precursor cells in the presence of interleukin 2.
Dröge W; Moyers C; Wehrmaker A; Schmidt H; Panknin S; Männel D; Falk W
J Immunol; 1984 Jun; 132(6):2749-59. PubMed ID: 6233360
[TBL] [Abstract][Full Text] [Related]
20. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage.
Larizza L; Schirrmacher V; Graf L; Pflüger E; Peres-Martinez M; Stöhr M
Int J Cancer; 1984 Nov; 34(5):699-707. PubMed ID: 6500746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
